inactivated influenza H7N9 vaccine

The inactivated influenza H7N9 vaccine is a monovalent vaccine candidate developed to protect against the H7N9 subtype of the Influenza A virus, which emerged in China in 2013 and poses a significant pandemic threat. The vaccine consists of inactivated (killed) virus particles or purified subunits, primarily the hemagglutinin (HA) protein, which serves as the main antigen to induce neutralizing antibodies. Because H7 antigens are typically poorly immunogenic in humans, these vaccines are frequently formulated with adjuvants, such as the oil-in-water emulsion AS03, to enhance the immune response and allow for dose sparing. Clinical development, supported by organizations like the NIAID, has evaluated various dosages and schedules to optimize safety and immunogenicity in healthy adults and elderly populations.

Other names

A/H7N9 Inactivated Influenza VaccineH7N9 IIVH-7N9 IIVH 7N9 IIVmonovalent inactivated influenza A/H7N9 virus vaccine